Overview
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.
Background
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.
Indication
Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.
Associated Conditions
- Paroxysmal Supraventricular Tachycardia (PSVT)
- Pulmonary Arterial Hypertension (PAH)
- SVT
- Supraventricular Tachycardia (SVT)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/28 | Phase 4 | Not yet recruiting | Anne E. Zepeski | ||
2024/12/05 | Phase 3 | Recruiting | Rashid Latif Medical College | ||
2024/08/29 | Phase 4 | Recruiting | |||
2022/04/04 | Not Applicable | Recruiting | |||
2022/02/10 | Phase 1 | Recruiting | Dwight Owen | ||
2021/08/20 | Phase 3 | Withdrawn | Vastra Gotaland Region | ||
2021/01/07 | Phase 4 | Completed | |||
2020/12/14 | Phase 4 | Recruiting | Vastra Gotaland Region | ||
2020/10/23 | Early Phase 1 | UNKNOWN | |||
2020/10/19 | Phase 2 | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Eugia US LLC | 55150-193 | INTRAVENOUS | 90 mg in 30 mL | 9/5/2023 | |
| Fresenius Kabi USA, LLC | 63323-651 | INTRAVENOUS | 3 mg in 1 mL | 11/20/2018 | |
| NorthStar Rx LLC | 16714-556 | INTRAVENOUS | 3 mg in 1 mL | 7/12/2022 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1631 | INTRAVENOUS | 3 mg in 1 mL | 4/28/2023 | |
| Meitheal Pharmaceuticals Inc. | 71288-207 | INTRAVENOUS | 3 mg in 1 mL | 4/14/2025 | |
| Akorn | 17478-542 | INTRAVENOUS | 3 mg in 1 mL | 1/29/2024 | |
| Mylan Institutional LLC | 67457-854 | INTRAVENOUS | 3 mg in 1 mL | 4/20/2022 | |
| Gland Pharma Limited | 68083-101 | INTRAVENOUS | 3 mg in 1 mL | 12/4/2017 | |
| Akorn | 17478-953 | INTRAVENOUS | 3 mg in 1 mL | 10/26/2017 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1511 | INTRAVENOUS | 3 mg in 1 mL | 1/22/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| CADEN SOLUTION FOR INJECTION 6 MG / 2 ML | SIN16391P | INJECTION, SOLUTION | 6 mg / 2 mL | 12/1/2021 | |
| ADENOCOR INJECTION 3MG/ML | SIN07679P | INJECTION | 6.0mg/2 ml | 4/5/1994 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Adenosine Injection | 国药准字H20253494 | 化学药品 | 注射剂 | 3/4/2025 | |
| Adenosine Injection | 国药准字H20253495 | 化学药品 | 注射剂 | 3/4/2025 | |
| Adenosine Injection | 国药准字H20233026 | 化学药品 | 注射剂 | 1/10/2023 | |
| Adenosine Injection | 国药准字H20174052 | 化学药品 | 注射剂 | 6/14/2022 | |
| Adenosine Injection | 国药准字H20237096 | 化学药品 | 注射剂 | 8/21/2023 | |
| Adenosine Injection | 国药准字H20249455 | 化学药品 | 注射剂 | 12/1/2024 | |
| Adenosine Injection | 国药准字H20249461 | 化学药品 | 注射剂 | 12/1/2024 | |
| Adenosine Injection | 国药准字H20174051 | 化学药品 | 注射剂 | 6/14/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| HEPATOSWISS FOR IV INFUSION INJ | N/A | N/A | N/A | 11/12/1982 | |
| HEPATOSWISS IM INJ | N/A | N/A | N/A | 8/13/1982 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| ADENOSCAN adenosine 30mg/10mL injection vial | 53226 | Medicine | A | 7/19/1996 | |
| ADENOSINE VIATRIS adenosine 6 mg/2 mL solution for injection vial | 152014 | Medicine | A | 8/10/2009 | |
| ADENOSINE VIATRIS adenosine 6 mg/2 mL injection pre-filled syringe | 152015 | Medicine | A | 8/10/2009 | |
| ADENOSINE BAXTER adenosine 30 mg/10 mL solution for infusion vial | 285931 | Medicine | A | 3/7/2018 | |
| ADSINE adenosine 6 mg/2 mL solution for injection vial | 285957 | Medicine | A | 3/7/2018 | |
| ADENOVIEW adenosine 30 mg/10 mL solution for injection vial | 176667 | Medicine | A | 2/16/2012 | |
| ADENOVIEW adenosine 60 mg/20 mL solution for injection vial | 152013 | Medicine | A | 8/10/2009 | |
| ADENOSINE JUNO adenosine 30 mg/10 mL solution for injection vial | 293816 | Medicine | A | 7/31/2018 | |
| ORTHOPLEX ADENOSINE | 20023 | Medicine | A | 10/3/1991 | |
| ADENOCOR Adenosine 6mg/2mL injection | 49439 | Medicine | A | 12/19/1994 |